Effects of inhaled Acetylcysteine combined with Moxifloxacin in treatment of patients with severe pneumonia
Objective:To observe effects of inhaled Acetylcysteine combined with Moxifloxacin in treatment of patients with severe pneumonia.Methods:A prospective study was conducted on 80 patients with severe pneumonia admitted to the hospital from January 2022 to August 2023.According to the random number table method,they were divided into control group and study group,40 cases in each group.The control group was treated with Moxifloxacin hydrochloride tablets,while the study group was treated with Acetylcysteine solution for inhalation on the basis of the control group.The therapeutic effects,the levels of lung function indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV1)],respiratory mechanics indexes[maximum expiratory flow(PEF),ratio of volume at peak tidal expiratory flow to expiratory tidal volume(VPEF/VE),tidal volume(VT)and ratio of time to peak tidal expiratory flow to total expiratory time(TPTEF/TE)],and inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),procalcitonin(PCT)],and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 95.00%(38/40),which was higher than 80.00%(32/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FVC and FEV1 in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of PEF,VPEF/VE,VT and TPTEF/TE in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of TNF-α,IL-6 and PCT in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Inhaled Acetylcysteine combined with Moxifloxacin in the treatment of the patients with severe pneumonia can improve the total effective rate of treatment,the levels of lung function indexes and the levels of inhalation mechanics indexes,and reduce the levels of inflammatory factors.Moreover,it is superior to single Moxifloxacin treatment.
NETL
NSTL
万方数据
维普
